Dr. Madanat earned his medical degree at the University of Jordan. He completed his residency training in internal medicine at the Cleveland Clinic, in Cleveland, Ohio. Drawn by the opportunity for harmonious integration of clinical medicine, pathophysiology of disease and novel treatment approaches, he completed his hematology and medical oncology fellowship at the Cleveland Clinic with clinical and research focus on myeloid malignancies; myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and acute myeloid leukemia.
Dr. Madanat’s decision to come to UTSW was influenced by the multi-disciplinary care provided in our malignant hematology and bone marrow transplantation department. He currently directs our myelodysplastic syndromes program. His clinical research interest lies in understanding the molecular and genomic drivers of disease and to better understand ways to incorporate novel therapies for our patients.
He has delivered several presentations and published numerous academic articles and book chapters that focus on the treatment of myeloid malignancies, acute leukemia, and myelodysplastic syndromes.
Dr. Madanat brings to UT Southwestern a strong background in malignant hematology and currently specializes in the treatment of patients with myelodysplastic syndromes. His clinical practice emphasizes a personalized approach in a patient and family-centered care. Dr. Madanat’s interests outside of medicine include his family, cooking and swimming.
- Medical School
- University of Jordan Faculty of Medicine, Jordan (2011)
- Al-Hussein Hospital, Jordan (2012), General Medicine & Surgery
- King Hussein Cancer Center, Jordan (2013), Internal Medicine
- Cleveland Clinic Foundation (2016), Internal Medicine
- Cleveland Clinic Foundation (2019), Hematology Oncology
- Incorporating novel therapies in the treatment paradigm of MDS
- Uncovering differences in stem cell biology in MDS
- Using genomic alterations to personalize therapy in MDS
- Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?
- Madanat YF, Kalaycio ME, Nazha A, Acta Med Acad 2019 Apr 48 1 35-44
- Wilms tumor 1 expression: addressing the 'elephant' in MDS.
- Madanat YF, Sekeres MA, Leuk. Lymphoma 2019 Mar 60 3 566-567
- Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?
- Madanat YF, Gerds AT, Best Pract Res Clin Haematol 2019 03 32 1 104-113
- Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
- Madanat YF, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B, Kalaycio M, Sekeres MA, Smith MR, Hill BT, Clin Lymphoma Myeloma Leuk 2017 Dec 17 12 857-862
- Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.
- Madanat Y, Sekeres MA, Semin. Hematol. 2017 07 54 3 147-153
- Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas.
- Madanat YF, Smith MR, Almasan A, Hill BT, Blood Lymphat Cancer 2016 6 1-6
- Got zinc? An exfoliative rash in a parenteral nutrition-dependent patient.
- Sidana S, Madanat Y, Pile J, J Gen Intern Med 2015 Apr 30 4 529-30
Myelodysplastic Syndromes. In Concise Guide to Hematology, 2nd Ed.
Madanat YF, Sekeres MA (2019). Springer International Publishing
Honors & Awards
- Abstract Achievement Award
American Society of Hematology (2018)
- Honorable Distinction Award
Society of Hematologic Oncology (2018)
- Abstract Achievement Award
American Society of Hematology (2017)
- MDS Foundation (2020)
- American Society of Clinical Oncology (2016)
- American Society of Hematology (2016)
- American College of Physicians (2013)
- American Medical Association (2013)